Celltrion Reports Post-hoc Analysis from LIBERTY Studies (CTRN)

Celltrion (CTRN) today released post-hoc analyses from its LIBERTY Phase 3 trials of tralokinumab for atopic dermatitis, showing significant improvements in skin clearance and quality-of-life measures compared to placebo. The data, presented at a major dermatology conference, support the drug's differentiated efficacy profile in moderate-to-severe AD. The company noted a 27% higher rate of complete skin clearance in tralokinumab-treated patients versus placebo at 16 weeks. Celltrion is advancing regulatory filings in key markets and plans additional studies to explore long-term benefits and safety.